Skip to content
Search

Latest Stories

Haleon not surprised by Pfizer stake sale plans, says CFO

Pfizer's plan to sell its Haleon stake is not a surprise, the consumer health company's finance chief Tobias Hestler told Reuters on Wednesday (3 May).

London-listed Haleon was carved out as an independent company in July and comprises consumer health assets once owned by GSK and Pfizer.


Pfizer, which has a 32% stake in the maker of Sensodyne toothpaste and Panadol painkillers, told the Financial Times on Tuesday that it intends to offload that stake in a "slow and methodical" manner within months.

Hestler said Pfizer has long been clear about its intention to sell off the stake, suggesting that the reason the potential of the selloff has gained traction is because the selling window opens around the time that Haleon's results are announced.

"This will happen every quarter from now until they're sold off...this is just what's expected," he said, adding: "If I get a courtesy call the evening before they do it then that would be nice, but they don't even have to do that."

Shares of the world's biggest standalone consumer health business were down more than 3% in early trading.

"These stock 'overhangs' can depress share prices in the short term, but it seems unlikely anyone will not buy a pack of Advil or Tums because Pfizer are thinking of selling a non-core investment," said Steve Clayton, head of equity funds at Hargreaves Lansdown.

Haleon, which sells non-prescription drugs, vitamins and oral care products, on Wednesday reported a fall in quarterly adjusted profit margin, mainly because of "cost inflation and incremental standalone costs".

Like its consumer staples competitors, Haleon has been subject to cost inflation, which rose during the COVID-19 pandemic and was exacerbated by Russia's invasion of Ukraine.

Apart from somewhat lower energy prices, most costs that make a difference to Haleon such as packaging, aluminium and labour are still rising, albeit at a slower pace, Hestler said.

"What I'm seeing right now is probably single digit cost inflation so there's still cost inflation coming through in the business, he said.

More For You

Pharmacy owners to receive 19p SAF increase in advance payments for April and May 2025

The Single Activity Fee (SAF) was increased by 19p to £1.46 per item, effective from April 2024.

gettyimages

19p SAF increase to be included in April and May 2025 advance payments

Following discussions with the Department of Health and Social Care (DHSC), Community Pharmacy England (CPE) has agreed a mechanism that will allow pharmacy owners to receive the 19p increase to the Single Activity Fee (SAF) earlier for the dispensing months of April and May 2025.

CPE said: “The advance payments for these dispensing months will be adjusted to incorporate the uplift to the SAF. No adjustment to advance payments will be required from the June 2025 dispensing month onwards.”

Keep ReadingShow less
CPE invites pharmacy owners to share their views on new CPCF funding settlement

What do you think should be the next priority for the Government?

gettyimages

Pharmacy owners asked to share their views on new CPCF arrangements

Community Pharmacy England (CPE) is urging pharmacy owners to share their views on the new Community Pharmacy Contractual Framework (CPCF) funding settlement ahead of its next full Committee meeting, scheduled for 30 April–1 May.

The Committee said it had agreed to the settlement "reluctantly," acknowledging that it represents a significant shift after years of real-terms funding cuts, while admitting that it’s “still not sufficient to match the continued scale of pressures facing pharmacy businesses.”

Keep ReadingShow less
Homecare medicines services face many challenges beyond pharmacy's control

Homecare medicines services face many challenges beyond pharmacy's control

gettyimages

GPhC calls for industry-wide collaboration to strengthen homecare medicines services

The General Pharmaceutical Council (GPhC) has called for industry-wide collaboration to improve homecare medicines services to ensure patients always receive their medicines when needed.

The call follows a recent review by the regulator, which identified several challenges facing homecare services, many of which were beyond the immediate control of the pharmacies providing them.

Keep ReadingShow less
Lack of funding deters NI pharmacy contractors from expanding portfolio

W G Hamilton Pharmacy is the third pharmacy in Northern Ireland to be recently sold to first-time buyers.

Pharmacy ownership trends shift in Northern Ireland due to funding gap

An increasing number of pharmacies in Northern Ireland are being acquired by first-time buyers, as existing contractors and groups pull back from expanding their portfolios amid ongoing funding pressures, according to specialist business property adviser Christie & Co.

Among the most recent sales is W G Hamilton Pharmacy, a busy community pharmacy in Ballysillan, North Belfast.

Keep ReadingShow less
RPS backs Pharmacist Support "Gift in Wills" initiative

The ‘Gift in Wills’ initiative is delivered in partnership with Bequeathed.

Photo credit: gettyimages

Leave a legacy: RPS partners with Pharmacist Support to promote ‘Gift in Wills’

The Royal Pharmaceutical Society (RPS) has announced its support for the ‘Gift in Wills’ initiative run by Pharmacist Support, coinciding with the charity’s birthday celebrations today (Tuesday 15 April).

This collaboration allows RPS members to create a free will while also helping to safeguard the future of vital support services for the pharmacy profession.

Keep ReadingShow less